Gynecologic Cancer clinical trials at University of California Health

5 in progress, 4 open to eligible people

Showing trials for

  • Exercise and Movement to Enhance Resiliency in Cancer Patients

    open to eligible females ages 18 years and up

    This is a single-center, pilot, hybrid type 1 design implementation study to evaluate the feasibility and implementation of a personalized digital exercise program and a virtual support group to improve patient-centered outcomes in patients receiving treatment for gynecologic cancer receiving treatment at University of California, San Francisco.

    at UCSF

  • First-in-Human Study of STX-478 as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors

    open to eligible people ages 18 years and up

    Study STX-478-101 is a multipart, open-label, phase 1/2 study evaluating the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of STX-478 in participants with advanced solid tumors with P13Ka mutations. Part 1 will evaluate STX-478 as monotherapy in participants with advanced solid tumors. Part 2 will evaluate STX-478 therapy as combination therapy with fulvestrant in participants with hormone receptor positive (HR+) breast cancer. Part 3 will evaluate STX-478 as combination therapy with fulvestrant and a CDK4/6 Inhibitor (either Ribociclib or Palbociclib) in participants with HR+ breast cancer. Each study part will include a 28-day screening period, followed by treatment with STX-478 monotherapy or combination therapy.

    at UCSF

  • Fatigue and Molecular Mechanisms in Cancer Patients Receiving CCRT

    open to eligible people ages 18 years and up

    Cancer-related fatigue (CRF) is a significant problem for cancer patients. This prospective, basic science, observational study will evaluate for changes in CRF associated with molecular characteristics prior to, during, and at the completion of non-investigational, standard-of-care, combined chemotherapy and radiation therapy (CCRT) and to develop and assess predictive models for CRF severity.

    at UCSF

  • PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery

    open to eligible females ages 18 years and up

    This study seeks to understand how frailty, a term that describes people who are more vulnerable stressors such as a new medical problem, affects the outcomes and quality of life in adult patients with gynecologic cancer.

    at UCSF

  • Lucitanib in Combination With Nivolumab in Patients With a Solid Tumor

    Sorry, currently not accepting new patients, but might later

    This is an open-label, Phase 1b/2 study to determine the recommended dose of lucitanib in combination with nivolumab in patients with an advanced solid tumor (Phase 1b); followed by evaluation of the safety and efficacy of lucitanib and nivolumab in patients with an advanced gynecological solid tumor (Phase 2) and evaluate the effects of dosing under fasting or fed state (Food Effect)

    at UCLA UCSD

Our lead scientists for Gynecologic Cancer research studies include .

Last updated: